⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ASND News
Ascendis Pharma A/S American Depositary Shares
Innovation with Purpose: NASM Launches ClaireAI™, the Industry’s First Trusted Virtual Mentor to Empower Fitness Professionals
globenewswire.com
ASND
Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035
globenewswire.com
PFE
MRK
LLY
ASND
IPN
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
globenewswire.com
ASND
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
globenewswire.com
ASND
Ascendis Pharma Reports Third Quarter 2025 Financial Results
globenewswire.com
ASND
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
globenewswire.com
ASND
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
globenewswire.com
ASND
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
globenewswire.com
ASND
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
globenewswire.com
ASND